Aerosolized vasodilators in pulmonary hypertension

Area of Science:

• Cardiology
• Pulmonology
• Pharmacology

Background:

• Pulmonary hypertension (PH) is a severe condition marked by elevated pulmonary artery pressure and vascular resistance.
• PH results from an imbalance between vasoconstrictive and vasodilative agents, impacting pulmonary circulation.
• Current treatments like intravenous vasodilators have systemic side effects due to lack of pulmonary selectivity.

Purpose of the Study:

• To evaluate aerosolized vasodilators as a targeted treatment for pulmonary hypertension.
• To assess the efficacy and safety of inhaled iloprost, a prostacyclin analogue, in managing PH.

Main Methods:

• Studies involving inhaled iloprost for alveolar deposition to achieve preferential pulmonary vasodilation.
• Comparison of inhaled iloprost's vasodilatory potency with intravenous prostacyclin.
• Clinical evaluation of long-term inhaled iloprost effects on exercise capacity and hemodynamics in PH patients.

Main Results:

• Inhaled iloprost demonstrated preferential vasorelaxation in the pulmonary circulation, matching intravenous prostacyclin's potency.
• Long-term use of inhaled iloprost showed sustained improvements in exercise capacity and pulmonary hemodynamics.
• The choice of nebulizer is critical for effective drug delivery and patient outcomes.

Conclusions:

• Aerosolized vasodilators, particularly inhaled iloprost, represent a well-established and promising therapeutic strategy for pulmonary hypertension.
• This approach offers targeted treatment with reduced systemic side effects compared to intravenous administration.